Taysha Gene Therapies Current Ratio 2020-2024 | TSHA

Taysha Gene Therapies current ratio from 2020 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Taysha Gene Therapies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-09-30 $0.16B $0.03B 5.51
2024-06-30 $0.18B $0.03B 5.22
2024-03-31 $0.13B $0.04B 3.38
2023-12-31 $0.15B $0.04B 4.08
2023-09-30 $0.17B $0.18B 0.95
2023-06-30 $0.05B $0.05B 1.07
2023-03-31 $0.07B $0.05B 1.33
2022-12-31 $0.10B $0.06B 1.54
2022-09-30 $0.04B $0.03B 1.30
2022-06-30 $0.08B $0.04B 1.79
2022-03-31 $0.11B $0.05B 2.20
2021-12-31 $0.16B $0.05B 3.08
2021-09-30 $0.20B $0.04B 4.56
2021-06-30 $0.21B $0.03B 7.30
2021-03-31 $0.24B $0.02B 12.64
2020-12-31 $0.26B $0.01B 36.17
2020-09-30 $0.28B $0.01B 24.02
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00